Daiichi to market Esperion's LDL-C lowering products in Europe

Esperion Therapeutics Inc. (NASDAQ:ESPR) will get $150 million cash up front in exchange

Read the full 134 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE